GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Health Industries Holdings Inc (OTCPK:CHHE) » Definitions » EBITDA

China Health Industries Holdings (China Health Industries Holdings) EBITDA : $-2.43 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is China Health Industries Holdings EBITDA?

China Health Industries Holdings's EBITDA for the three months ended in Dec. 2023 was $-0.36 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.43 Mil.

During the past 12 months, the average EBITDA Growth Rate of China Health Industries Holdings was -1115.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of China Health Industries Holdings was 425.00% per year. The lowest was -70.80% per year. And the median was 47.40% per year.

China Health Industries Holdings's EBITDA per Share for the three months ended in Dec. 2023 was $-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.04.

During the past 12 months, the average EBITDA per Share Growth Rate of China Health Industries Holdings was -1333.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of China Health Industries Holdings was 63.90% per year. The lowest was -71.30% per year. And the median was 46.00% per year.


China Health Industries Holdings EBITDA Historical Data

The historical data trend for China Health Industries Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Health Industries Holdings EBITDA Chart

China Health Industries Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.51 5.82 2.90 -0.82 -1.16

China Health Industries Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 -0.11 -1.87 -0.09 -0.36

Competitive Comparison of China Health Industries Holdings's EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, China Health Industries Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Health Industries Holdings's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Health Industries Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China Health Industries Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

China Health Industries Holdings's EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

China Health Industries Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Jun. 2023, China Health Industries Holdings's EBITDA was $-1.16 Mil.

China Health Industries Holdings's EBITDA for the quarter that ended in Dec. 2023 is calculated as

China Health Industries Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, China Health Industries Holdings's EBITDA was $-0.36 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

China Health Industries Holdings  (OTCPK:CHHE) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


China Health Industries Holdings EBITDA Related Terms

Thank you for viewing the detailed overview of China Health Industries Holdings's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


China Health Industries Holdings (China Health Industries Holdings) Business Description

Traded in Other Exchanges
N/A
Address
3199-1 Longxiang Road, Songbei District, Heilongjiang Province, Harbin, CHN, 150028
China Health Industries Holdings Inc operates in the health product industry and produces, markets and distributes medicines, health products, health devices and cosmetics. Its products series cover hemp-based food, hemp-based medicines, external used medicines and health food. The company has segmented its operating activities into three reportable segments, Humankind, HLJ Huimeijia, and Others. It generates maximum revenue from the Humankind segment.
Executives
Sun Xin director, 10 percent owner, officer: CEO, CFO and Treasurer NO 168 BINBEI STREET, SONBEI DISTRICT, HARBIN, HEI LONG JIANG F4 150000
Hall E Ewing director, officer: Secretary 2737 W BASELINE RD 22, TEMPE AZ 85283
Jack C Robinson director 16304 E COUNTRY SHADOW CT, LILBEAT AZ 85297
Teri S Foster director 402 CANDOVER COURT, KATY TX 77450
Brian Lee Hahn director, officer: COO 422 LAMONT TERRACE, BUFFALO GROVE IL 60089
Dennis Mckee 10 percent owner 3522 DOHERTY PLACE, KATY TX 77449
Thomas Allen Bontems 10 percent owner, officer: President, CEO, CFO and, other: Secretary 1808 S. 1ST AVENUE, PHONEIX AZ 85003

China Health Industries Holdings (China Health Industries Holdings) Headlines

No Headlines